William Oh, MD
The management of metastatic hormone-sensitive prostate cancer continues to evolve as new findings emerge, such as results from the LATITUDE and CHAARTED studies.
, William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor, Medicine and Urology, Mount Sinai School of Medicine, associate director, Clinical Research, The Tisch Cancer Institute, discussed treatment with abiraterone versus docetaxel in patients with prostate cancer, other remaining questions in the field, and what role immunotherapy is poised to play.
OncLive: What questions surround abiraterone versus docetaxel in the treatment in prostate cancer?
One of the biggest developments in the treatment of advanced prostate cancer over the past several years has been the management of metastatic hormone-sensitive prostate cancer. This is primarily in patients who are newly diagnosed. In 2014, a plenary session at the ASCO Annual Meeting presented the results of CHAARTED. The results, favoring the use of early chemotherapy, were subsequently published in the New England Journal of Medicine
. A second study, STAMPEDE, confirmed those findings. At that time, we started using docetaxel in the treatment of newly diagnosed metastatic disease.
... to read the full story